Abstract
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung cancer. This open-label, pa......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
